Search
Temazepam
go.drugbank.com/drugs/DB00231ApprovedIn particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to … Although the chemical synthesis of temazepam was established by 1965 [A175333], mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted
Products: Co Temazepam Capsules 15mg, Co Temazepam Capsules 30mgZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalA decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … blood and to various extracerebral tissues.
Mixtures: MADOPAR 125 T, MADOPAR 125 TDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249010] Vutrisiran was approved by the FDA in June 2022.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Categories: sipuleucel-TSynonyms: Sipuleucel-TIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Categories: Agents to Treat Airway DiseaseLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnIt has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety. … voluntarily withdraw these products from the U.S. market, and the company has submitted a request to voluntarily withdraw the drug.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGuanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnIt is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. … An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.
Succinylcholine
go.drugbank.com/drugs/DB00202ApprovedInvestigationalSuccinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. … Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short